Celltrion is expanding its market presence in Peru, a major Latin American country, by winning a series of successful public tenders.First of all, Truxima (rituximab) 500 mg won a tender held by the National Health Ministry of Peru (Centro Nacional de Abastecimiento de Recursos Estratégicos en Salud
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.The MARIPOSA study has proven the feasibility of lazertinib+amivantamab as a standard first-line treatment. Competing trial FLAURA2 is expected to underperform in terms of OS. In addition, ESMO clini
Yuhan Pharmaceuticals’ lung cancer drug Leclaza has demonstrated enhanced efficacy when combined with Johnson & Johnson’s (J&J) lung cancer treatment. Detailed data is set to be presented at a global conference on Oct. 23, heightening market anticipation.According to industry sources on Oct. 4, Yuha
The author is an analyst for NH Investment & Securities. He can be reached at kyuha.lee@nhqv.com -- Ed.Phase III MARIPOSA meets primary endpointJanssen announced positive topline results from the pivotal phase III MARIPOSA study evaluating Rybrevant (amivantamab) in combination with lazertinib, a th
Celltrion announced on Sept. 4 that it recently obtained sales approval for its Avastin (bevacizumab) biosimilar Vegzelma from the Australian Therapeutic Goods Administration (TGA).Celltrion has been granted sales approval for Vegzelma in Australia for the entire range of indications approved for Av
The trend of collaborations between domestic and foreign enterprises of various sizes to achieve success in new drug development is on the rise. Such collaborations are viewed within the industry as a potential model for “Korean-style Open Innovation” in the pharmaceutical and biotech sectors.Accord
Yuhan Corporation announced on May 30 that it has signed a technology licensing agreement with J INTS BIO for the tyrosine kinase inhibitor (TKI) “JIN-A04” targeting HER2.The total contract size amounts to 429.8 billion won (US$325.8 million), inclusive of an upfront payment of 25 billion won (US$19
The author is an analysts of NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.At Yuhan, 1Q23 non-consolidated and consolidated OP likely came in at respective W14.6bn (beating consensus) and W13.3bn (missing consensus). We anticipate consolidated earnings improvement after com
Daewoong Pharmaceutical announced on Jan. 5 that it signed a contract with Oncorus of the United States on Jan. 4 for joint R&D and commercialization of lipid nanoparticle (LNP) mRNA drugs.Oncorus is a U.S. a biopharmaceutical company focused on developing next-generation RNA-based immunotherapies.T
The authors are analysts of Shinhan Securities. They can be reached at shawn1225@shinhan.com and jhwon@shinhan.com, respectively. – Ed. US partner Spectrum receives CRL from FDA for poziotinibSpectrum Pharmaceuticals, Hanmi Pharm’s US partner for the non-small cell lung cancer treatment candidate po
Boryung (formerly Boryung Pharmaceutical) announced on Oct. 25 that it has signed an asset acquisition agreement for ‘Alimta (API: pemetrexed)’, a non-small cell lung cancer (NSCLC) treatment, with Eli Lilly and Co. The completion of this transaction is subject to customary regulatory reviews and cl
The authors are analysts of Shinhan Investment Corp. They can be reached at sehunjang@shinhan.com and shawn1225@shinhan.com, respectively. -- Ed. 3Q22 preview: Sales likely in line with market expectationsWe now expect Yuhan to post sales of KRW486.6bn (+7.8% YoY) for 3Q22, in line with the market c
Spectrum Pharmaceuticals, a U.S. biopharmaceutical company that has licensed poziotinib from Korea's Hanmi Pharmaceutical, announced on Sept. 22 that the U.S. Food and Drug Administration’s (“FDA”) Oncologic Drugs Advisory Committee (“ODAC”) met to review poziotinib for the treatment of patients
Hanmi Pharmaceutical has obtained U.S. approval for its neutropenia treatment Rolontis, opening a new chapter in its R&D history. It is the first drug that Hanmi has succeeded in commercializing in the global market.Spectrum Pharmaceuticals, a U.S. partner to which Hanmi Pharmaceutical licensed out
Chong Kun Dang announced on Sept. 13 that it shared the results of the Phase 1 clinical trial on CKD-702, a new anticancer dual antibody biotech drug, at the European Society for Medical Oncology (ESMO) annual conference held in Paris, France from Sept. 9 to 13.Since May 2020, Chong Kun Dang has bee
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Hanmi Pharm posted consolidated 2Q22 sales of W316.5bn and OP of W29.6bn, with OP coming in slightly below our estimate. Beijing Hanmi led consolidated OP growth, booking OP of W17.1bn. The strength
The authors are analysts of Shinhan Investment Corp. They can be reached at shawn1225@shinhan.com and sehunjang@shinhan.com, respectively. – Ed. Biotech stocks on a losing streak since 2021Biotech stocks have continued on a losing streak in 1H22. Investor appetite for growth stocks has declined in t
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. ctDNA technology a game changerAt this year’s ASCO conference, circulating tumor DNA (ctDNA) was at the center of attention. Though various technological challenges need to be tackled first for full-
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Although the global bio sector index continues to be sluggish, we believe it will be important to pay close attention to global clinical trial data for ADC and KRAS inhibitors at 2022 ASCO (Jun 3~7).
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Hanmi Pharm posted consolidated 1Q22 sales of W321.1bn and OP of W38.7bn, in line with our estimates, thanks to Beijing Hanmi and business normalization amid the easing of the Covid-19 pandemic. Glob